Resonant Capital Advisors LLC Sells 1,162 Shares of CVS Health Co. (NYSE:CVS)

Resonant Capital Advisors LLC lowered its stake in CVS Health Co. (NYSE:CVS) by 2.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 41,161 shares of the pharmacy operator’s stock after selling 1,162 shares during the period. Resonant Capital Advisors LLC’s holdings in CVS Health were worth $3,250,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of CVS. Cantor Fitzgerald Investment Advisor L.P increased its position in shares of CVS Health by 92.9% in the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 377,875 shares of the pharmacy operator’s stock worth $38,245,000 after purchasing an additional 181,966 shares during the period. United Bank increased its position in shares of CVS Health by 7.2% in the first quarter. United Bank now owns 18,658 shares of the pharmacy operator’s stock worth $1,888,000 after purchasing an additional 1,260 shares during the period. Loomis Sayles & Co. L P increased its position in shares of CVS Health by 4,063.8% in the first quarter. Loomis Sayles & Co. L P now owns 12,075 shares of the pharmacy operator’s stock worth $1,222,000 after purchasing an additional 11,785 shares during the period. Zions Bancorporation N.A. increased its position in shares of CVS Health by 116.9% in the first quarter. Zions Bancorporation N.A. now owns 2,572 shares of the pharmacy operator’s stock worth $260,000 after purchasing an additional 1,386 shares during the period. Finally, Ergoteles LLC bought a new position in shares of CVS Health in the first quarter worth $1,551,000. Institutional investors own 80.66% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. HSBC assumed coverage on CVS Health in a research report on Friday, December 22nd. They issued a “buy” rating and a $94.00 target price on the stock. Wells Fargo & Company decreased their target price on CVS Health from $83.00 to $76.00 and set an “equal weight” rating on the stock in a research report on Monday, April 8th. Royal Bank of Canada decreased their target price on CVS Health from $86.00 to $84.00 and set an “outperform” rating on the stock in a research report on Thursday, February 8th. SVB Leerink began coverage on CVS Health in a research report on Monday, February 26th. They issued an “outperform” rating and a $88.00 target price on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $87.00 price target on shares of CVS Health in a report on Wednesday, April 10th. Four investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $89.44.

Insider Transactions at CVS Health

In other news, EVP Prem S. Shah sold 29,473 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $76.95, for a total transaction of $2,267,947.35. Following the transaction, the executive vice president now directly owns 39,765 shares of the company’s stock, valued at $3,059,916.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.24% of the stock is owned by insiders.

CVS Health Trading Up 1.3 %

Shares of CVS Health stock traded up $0.92 on Friday, reaching $69.65. 5,632,495 shares of the company’s stock were exchanged, compared to its average volume of 10,822,887. The company has a market capitalization of $87.79 billion, a P/E ratio of 10.75, a price-to-earnings-growth ratio of 0.91 and a beta of 0.52. CVS Health Co. has a 52 week low of $64.41 and a 52 week high of $83.25. The firm’s 50-day moving average is $75.42 and its two-hundred day moving average is $73.70. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.63 and a current ratio of 0.86.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, February 7th. The pharmacy operator reported $2.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.01 by $0.11. CVS Health had a return on equity of 15.25% and a net margin of 2.33%. The firm had revenue of $93.81 billion for the quarter, compared to analysts’ expectations of $90.58 billion. During the same period in the prior year, the business earned $1.99 EPS. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. Sell-side analysts predict that CVS Health Co. will post 8.32 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Monday, April 22nd will be given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.82%. The ex-dividend date is Friday, April 19th. CVS Health’s payout ratio is 41.18%.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.